U.S. President Donald Trump said Americans are paying more than people in other countries for prescription drugs, according to excerpts from the State of the Union address.
Roche aims to broaden the use of the Swiss drugmaker’s Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of the company’s older mainstay product Herceptin.
A powerful U.S. Senate committee invited seven pharmaceutical companies to testify at a hearing during February 2019 examining rising prescription drug prices.
U.S. Senator Bernie Sanders sent a letter to Catalyst Pharmaceuticals asking the company to justify the decision to charge $375,000 annually for a medication that for years has been available to patients for free.
As lawmakers in Congress are exploring potential price-lowering options for prescription drugs, Department of Health and Human Services Secretary Alex Azar is floating a proposed rule to lower the prices and out-of-pocket expenses by encouraging manufacturers to pass discounts to patients instead of insurers.
Novartis’ Kymriah won the blessing of health authorities in England for adult lymphoma patients, the Swiss drugmaker said, reversing the 2018 rejection of the cell therapy.
Many of the largest U.S. pharmacies and drug distributors do not have Teva Pharmaceutical Industries Ltd.’s generic version of EpiPen five months after the life-saving allergy treatment was approved for sale in the United States, pharmacy chains and a group that tracks drug shortages told Reuters.
Two powerful U.S. lawmakers sent letters to the three leading insulin manufacturers requesting information on why its cost has skyrocketed in recent years and how much the companies profit from the life-sustaining diabetes treatment.
The U.S. Senate Finance Committee and the House Oversight Committee started hearings focused on high drug prices.